ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,094 GBX | +0.32% |
|
-1.76% | +14.04% |
| Jul. 05 | AstraZeneca's Tagrisso Approved by EU as First-Line Treatment for Non-Small Cell Lung Cancer | MT |
| Jul. 05 | AstraZeneca: cancer treatment approved by the EU | CF |
Financials (USD)
| Sales 2024 * | 51.57B | Sales 2025 * | 55.42B | Capitalization | 239B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.74B | Net income 2025 * | 10.47B | EV / Sales 2024 * | 5.05 x |
| Net Debt 2024 * | 20.83B | Net Debt 2025 * | 14.28B | EV / Sales 2025 * | 4.58 x |
| P/E ratio 2024 * |
27.4
x | P/E ratio 2025 * |
22.8
x | Employees | 89,900 |
| Yield 2024 * |
1.99% | Yield 2025 * |
2.1% | Free-Float | 96.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | +0.09% | ||
| 1 week | -2.34% | ||
| Current month | -2.75% | ||
| 1 month | -4.63% | ||
| 3 months | +13.25% | ||
| 6 months | +11.55% | ||
| Current year | +13.36% |
1 week
11 946.00
12 378.00
1 month
11 946.0012 704.00
Current year
9 461.0012 704.00
1 year
9 461.0012 704.00
3 years
8 029.0012 704.00
5 years
5 871.0012 704.00
10 years
3 680.0012 704.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 66 | 17-09-30 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Director/Board Member | 68 | 99-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 218 M€ | +16.82% | ||
| 5.17% | 21 M€ | +10.60% | - | |
| 4.89% | 801 M€ | +10.23% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-08 | 12,086 | +0.25% | 60 706 |
| 24-07-05 | 12,056 | -0.41% | 1,079,172 |
| 24-07-04 | 12,106 | +0.72% | 1,130,254 |
| 24-07-03 | 12,020 | -0.55% | 2,172,456 |
| 24-07-02 | 12,086 | -1.77% | 1,577,420 |
Delayed Quote London S.E., July 08, 2024 at 03:05 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
154.4
USD
Average target price
174.6
USD
Spread / Average Target
+13.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.36% | 239B | |
| +56.89% | 823B | |
| +40.02% | 627B | |
| -6.55% | 353B | |
| +15.99% | 320B | |
| +7.92% | 295B | |
| +13.79% | 220B | |
| -0.49% | 219B | |
| +7.94% | 167B | |
| -2.57% | 159B |
- Stock Market
- Equities
- AZN Stock
